Rivaroxaban for prevention and treatment of venous thromboembolism

被引：9
|
作者：
Chan, Noel C. [1 ,2 ]
Weitz, Jeffrey, I [1 ,2 ]
机构：
[1] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada
[2] McMaster Univ, Dept Med, Hamilton, ON, Canada
来源：
FUTURE CARDIOLOGY | 2019年 / 15卷 / 02期
关键词：
nonvitamin K oral antagonist; rivaroxaban; venous thromboembolism; FACTOR-XA INHIBITOR; DIRECT ORAL ANTICOAGULANTS; DEEP-VEIN THROMBOSIS; TOTAL HIP; ORTHOPEDIC-SURGERY; EXTENDED TREATMENT; KNEE REPLACEMENT; REAL-WORLD; ENOXAPARIN; THROMBOPROPHYLAXIS;
D O I：
10.2217/fca-2018-0076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Until recently, heparins and vitamin K antagonists (VKAs) were the cornerstones for prevention and treatment of venous thromboembolism (VTE). This situation changed with the introduction of the direct oral anticoagulants, which are now replacing low-molecular-weight heparin for thromboprophylaxis after elective hip or knee arthroplasty and VKAs for VTE treatment. Rivaroxaban, an oral factor Xa inhibitor, was the first direct oral anticoagulant licensed for VTE prevention and treatment. This paper provides the rationale for factor Xa as a target for anticoagulants, describes the development of rivaroxaban, reviews its pharmacological profile, discusses the clinical trials with rivaroxaban for VTE prevention and treatment and highlights areas of uncertainty.
引用
收藏
页码：63 / 77
页数：15
相关论文
共 50 条
  • [21] Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism
    Crowther, Mark A.
    Cuker, Adam
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (13): : 1279 - 1280
  • [22] Treatment and prevention of venous thromboembolism
    Hull, RD
    Pineo, GF
    Valentine, KA
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1998, 24 : 21 - 31
  • [23] Prevention and treatment of venous thromboembolism
    Casadei, Barbara
    Cosentino, Francesco
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0C) : C1 - C1
  • [24] Prevention and treatment of venous thromboembolism
    Pineo, GF
    Hull, RD
    DRUGS, 1996, 52 (01) : 71 - 92
  • [25] Treatment and prevention of venous thromboembolism
    Verhaeghe, R
    Carreras, LO
    THROMBOSIS: FUNDAMENTAL AND CLINICAL ASPECTS, 2003, : 521 - 545
  • [26] Rivaroxaban - a new drug in the treatment of symptomatic venous thromboembolism
    Wolkowska, Katarzyna
    KARDIOLOGIA POLSKA, 2011, 69 (03) : 298 - 301
  • [27] Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies
    Khorana, Alok A.
    Weitz, Jeffrey I.
    THROMBOSIS AND HAEMOSTASIS, 2018, 118 : S23 - S33
  • [28] Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data
    Beyer-Westendorf, Jan
    Cohen, Alexander T.
    Monreal, Manuel
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2015, 17 (0D) : D32 - D41
  • [29] Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism
    Weitz, Jeffrey I.
    Bauersachs, Rupert
    Beyer-Westendorf, Jan
    Bounameaux, Henri
    Brighton, Timothy A.
    Cohen, Alexander T.
    Davidson, Bruce L.
    Holberg, Gerlind
    Kakkar, Ajay
    Lensing, Anthonie W. A.
    Prins, Martin
    Haskell, Lloyd
    van Belien, Bonno
    Verhamme, Peter
    Wells, Philip S.
    Prandoni, Paolo
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (03) : 645 - 650
  • [30] A Case of Cerebral Infarction During Treatment With Rivaroxaban for Venous Thromboembolism
    Kitahara, Kanayuki
    Momo, Kenji
    Nimura, Satomi
    Okazaki, Keinosuke
    Suzuki, Norihiro
    Kubota, Yutaro
    Tsunoda, Takuya
    Watanabe, Daishi
    Mizuma, Keita
    Ono, Kenjiro
    Sasaki, Tadanori
    AMERICAN JOURNAL OF THERAPEUTICS, 2022, 29 (06) : E673 - E676
12345